Powerful Sample Prep and LC Column Solutions for Forensic Toxicology Applications
|
|
- Oswin McDowell
- 5 years ago
- Views:
Transcription
1 Thank you for joining us! Our session will begin shortly Powerful Sample Prep and LC Column Solutions for Forensic Toxicology Applications While you are waiting, please feel free to browse our library of program content: Also, click below to learn more about CORTECS, our newest Solid-Core LC Column platform: Waters Corporation 1
2 Friendly Reminders Please use text chat functionality to submit your questions today. Providing Live Technical Support during today s event Poll Questions Audience participation Upon conclusion, follow up information will be available: Recorded version of today s presentation PDF Copy of today s slides Application specific discount offers CORTECS, Oasis, Ostro, BEH Columns Product specific information and reference materials 2013 Waters Corporation 2
3 About Today s Presenter Jonathan Danaceau, Ph.D., Senior Applications Chemist, Waters Corporation Dr. Jonathan Danaceau is a Senior Applications Chemist within Waters Consumable Business Unit. Jon received his B.S. in Biology from Allegheny College (Meadville, PA) and his Ph.D. in Neuroscience from the University of Utah (Salt Lake City, UT). Jon has an extensive background in bioanalysis including experience in the pharmaceutical industry, forensic toxicology, and anti-doping analysis. Jon joined Waters Chemistry Applied Technology group in 2011 where he has been focusing on sample preparation and chromatography solutions for various applications, including forensic toxicology and clinical research Waters Corporation 3
4 Sample Preparation and LC Column Solutions for Forensic Toxicology Applications Jonathan Danaceau, Ph.D. Senior Applications Chemist Waters Corporation 2013 Waters Corporation 4
5 Overview Goal of Sample Preparation Sample Preparation Options Application Examples Opioids and metabolites in urine and oral fluid Synthetic cannabinoids in urine and whole blood THC and metabolites in whole blood Expanded Toxicology Panel from Urine Summary 2013 Waters Corporation 5
6 Overview Goal of Sample Preparation Sample Preparation Options Application Examples Opioids and metabolites in urine, whole blood and oral fluid Synthetic cannabinoids in urine and whole blood Synthetic cathinones Bath Salts in urine THC and metabolites in whole blood Summary 2013 Waters Corporation 6
7 Goal of Sample Preparation Provides the target analyte(s) in solution Provides the analyte(s) at a concentration appropriate for detection or measurement Concentrating the analyte helps increase sensitivity and achieve lower limits of detection Removes interfering matrix elements (such as phospholipids, salts, proteins, nucleic acids, sugars, etc.) that alter the MS response or co-elute with the target analyte Matrix effects result in ion suppression (loss of signal) or ion enhancement (gain in signal) Matrix effects have a negative impact on the accuracy, precision, and robustness of the method; add to method variability 2013 Waters Corporation 7
8 Importance of Clean Samples Having cleaner samples means: Better chromatography Lower limits of detection Decreases assay variability; more robust assay o Reduced matrix effects o Fewer reanalyses o Less chance of false positives/negatives Longer column lifetime Less instrument downtime Minimize costs in manpower and equipment maintenance Sample Prep makes your analytical lab more productive! 2013 Waters Corporation 8
9 Sample Preparation Options Technique Advantages Disadvantages Appropriate Matrices Nonselective Dilution Simple Cheap Easy to automate No cleanup No enrichment Non-selective Urine Highly selective 2013 Waters Corporation 9
10 Sample Preparation Options Technique Advantages Disadvantages Appropriate Matrices Nonselective Dilution Simple Cheap Easy to automate No cleanup No enrichment Non-selective Urine Protein Precipitation Simple Quick Minimal method development Minimal selectivity; does not remove most matrix interferences No enrichment Substantial solvent evaporation may be needed Whole blood, plasma, serum Highly selective 2013 Waters Corporation 10
11 Sample Preparation Options Technique Advantages Disadvantages Appropriate Matrices Nonselective Dilution Simple Cheap Easy to automate No cleanup No enrichment Non-selective Urine Protein Precipitation Simple Quick Minimal method development Minimal selectivity; does not remove most matrix interferences No enrichment Substantial solvent evaporation may be needed Whole blood, plasma, serum Lipid/protein removal plates Simple, universal method Quick Minimal method development Minimal selectivity No enrichment Substantial solvent evaporation may be needed Whole blood, plasma, serum Highly selective 2013 Waters Corporation 11
12 Sample Preparation Options Technique Advantages Disadvantages Appropriate Matrices Nonselective Dilution Simple Cheap Easy to automate No cleanup No enrichment Non-selective Urine Protein Precipitation Simple Quick Minimal method development Minimal selectivity; does not remove most matrix interferences No enrichment Substantial solvent evaporation may be needed Whole blood, plasma, serum Lipid/protein removal plates Simple, universal method Quick Minimal method development Minimal selectivity No enrichment Substantial solvent evaporation may be needed Whole blood, plasma, serum Liquid-Liquid Extraction Offers better clean up than protein precipitation Can be optimized for different compound classes Less selective than SPE; does not remove endogenous phospholipids Cumbersome; requires user intervention Difficult to automate Not ideal for highly polar drugs and metabolites Solvent evaporation needed Urine, plasma, serum, oral fluid Highly selective 2013 Waters Corporation 12
13 Sample Preparation Options Technique Advantages Disadvantages Appropriate Matrices Nonselective Dilution Simple Cheap Easy to automate No cleanup No enrichment Non-selective Urine Protein Precipitation Simple Quick Minimal method development Minimal selectivity; does not remove most matrix interferences No enrichment Substantial solvent evaporation may be needed Whole blood, plasma, serum Lipid/protein removal plates Simple, universal method Quick Minimal method development Minimal selectivity No enrichment Substantial solvent evaporation may be needed Whole blood, plasma, serum Liquid-Liquid Extraction Solid-Phase Extraction (SPE) Offers better clean up than protein precipitation Can be optimized for different compound classes Best cleanup option Fast; easy to automate Achieves the highest recovery and reproducibility Can be manipulated for optimum recovery and cleanup Variety of device formats and sorbent chemistries Less selective than SPE; does not remove endogenous phospholipids Cumbersome; requires user intervention Difficult to automate Not ideal for highly polar drugs and metabolites Solvent evaporation needed May require method development to optimize the protocol Perceived to be difficult and costly Urine, plasma, serum, oral fluid Urine, whole blood, plasma, serum, oral fluid Highly selective 2013 Waters Corporation 13
14 Sample Preparation Options Technique Advantages Disadvantages Appropriate Matrices Nonselective Dilution Simple Cheap Easy to automate No cleanup No enrichment Non-selective Urine Protein Precipitation Simple Quick Minimal method development Minimal selectivity; does not remove most matrix interferences No enrichment Substantial solvent evaporation may be needed Whole blood, plasma, serum Lipid/protein removal plates Simple, universal method Quick Minimal method development Minimal selectivity No enrichment Substantial solvent evaporation may be needed Whole blood, plasma, serum Liquid-Liquid Extraction Solid-Phase Extraction (SPE) Offers better clean up than protein precipitation Can be optimized for different compound classes Best cleanup option Fast; easy to automate Achieves the highest recovery and reproducibility Can be manipulated for optimum recovery and cleanup Variety of device formats and sorbent chemistries Less selective than SPE; does not remove endogenous phospholipids Cumbersome; requires user intervention Difficult to automate Not ideal for highly polar drugs and metabolites Solvent evaporation needed May require method development to optimize the protocol Perceived to be difficult and costly Urine, plasma, serum, oral fluid Urine, whole blood, plasma, serum, oral fluid Highly selective 2013 Waters Corporation 14
15 Solid-Phase Extraction (SPE) SPE is gaining acceptance in clinical and forensic labs Cleans up, concentrates, and produces a final sample that is in an appropriate solvent for further analysis Uses polymeric or silica-based chromatographic particles packed into a variety of formats 96-well plates, cartridges, etc. SPE is considered to be a very versatile sample preparation technique for various analytes in complex matrices Blood, serum, plasma, oral fluid, tears, nasal fluid, CSF, urine, feces, meconium, postmortem samples, and many more! It s the best technique for minimizing matrix interferences including proteins, phospholipids, salts, and other endogenous compounds 2013 Waters Corporation 15
16 Oasis Family of Sorbents: Reversed-Phase and Mixed-ModeMode Sorbent ALWAYS Charged (-) Sorbent ALWAYS Charged (+) Selective for Basic Compounds Selective for Acidic Compounds Selective for Strong Basic Compounds For wide range of acidic, basic, and neutral compounds Selective for Strong Acidic Compounds Sorbent charged (-) at high ph; unionized at low ph Sorbent charged (+) at Low ph; unionized at high ph 2013 Waters Corporation 16
17 Oasis Family of Sorbents: Reversed-Phase and Mixed-ModeMode Sorbent ALWAYS Charged (-) Sorbent ALWAYS Charged (+) Selective for Basic Compounds Selective for Acidic Compounds Selective for Strong Basic Compounds For wide range of acidic, basic, and neutral compounds Selective for Strong Acidic Compounds Sorbent charged (-) at high ph; unionized at low ph Sorbent charged (+) at Low ph; unionized at high ph 2013 Waters Corporation 17
18 Waters SPE Device Formats Formats 96-well plates (with 5, 10, 30, 60 mg of sorbent) Syringe barrel cartridges Glass cartridges Online columns µelution plates How to process samples? Gravity Pressure Vacuum Automation 2013 Waters Corporation 18
19 Ostro 96-Well Sample Preparation Plate Cleanup of phospholipids and proteins in plasma and serum (also blood) Fast, easy in-well protein precipitation; precipitated proteins and phospholipids are left behind in the wells Significant time savings; protocol eliminates extract transfer and evaporation steps (also in plate format) Generic protocol; no method development Extracts can often be directly injected and analyzed Suitable for a wide variety of acidic, basic, and neutral compounds Pass-through method 2013 Waters Corporation 19
20 Phospholipids Remaining in the Extract: Ostro vs. LLE and PPT 100 % LLE with 5% NH 4 OH in MTBE MRM of m/z > (Lipid 184) 2.00e LLE with MTBE > (Lipid 184) 2.00e % Ostro > (Lipid 184) 2.00e8 % % PPT > (Lipid 184) 2.00e Time Ostro is superior to LLE and PPT for phospholipid removal 2013 Waters Corporation 20
21 Overview Goal of Sample Preparation Sample Preparation Options Application Examples Opioids and Metabolites in Urine Summary 2013 Waters Corporation 21
22 Opioids and Metabolites in Urine Assay Use Quantification of opioids and metabolites in urine Analytes 26 natural opiate drugs, semi-synthetic opioids, and synthetic narcotic analgesic compounds Goals Increase sample cleanliness, sensitivity and accuracy compared to sample dilution Accurate quantification of a comprehensive panel of opioid drugs and metabolites Direct analysis of glucuronide metabolites without hydrolysis 2013 Waters Corporation 22
23 Comprehensive opioid panel Compound 1 Morphine-3β-D-glucuronide 2 Oxymorphone-3β-D-glucuronide 3 Hydromorphone-3β-D- glucuronide 4 Morphine-6β-D-glucuronide 5 Morphine 6 Oxymorphone 7 Hydromorphone 8 Codeine-6β-D-glucuronide 9 Dihydrocodeine 10 Codeine 11 Oxycodone 12 6-Acetylmorphone (6-AM) 13 O-desmethyl Tramadol 14 Hydrocodone 15 Norbuprenorphine-glucuronide 16 Norfentanyl 17 Tramadol 18 Normeperedine 19 Meperidine 20 Buprenorphine-glucuronide 21 Norbuprenorphine 22 Fentanyl 23 Buprenorphine 24 EDDP+ 25 Propoxyphene 26 Methadone Natural opiates and metabolites Semi-synthetic opioids Synthetic narcotic analgesics All bases Oasis MCX 2013 Waters Corporation 23
24 Extraction Methodologies for Urine Oasis MCX µelution Plate Protocol (Mixed-mode strong cation exchange SPE) Sample Pretreatment 100 µl urine µl 4% H 3 PO µl IS Condition Plate 200 µl MeOH then 200 µl Water Load 300 µl pretreated sample Wash 200 µl Water, then 200 µl MeOH Elute 2 x 50 µl (60:40 ACN:MeOH + 5% NH 4 OH) Sample Dilution Protocol 100 µl urine Add 100 µl IS (dissolved in water) Vortex Inject 10 µl A short evaporation step (<5 min) implemented to evaporate and reconstitute in the mobile phase Prevents solvent effects for early eluting compounds Evaporate under N 37 o C Reconstitute in 50 µl of starting mobile phase (2% ACN/0.1% FA) Inject 10 µl 2013 Waters Corporation 24
25 UPLC and MS conditions UPLC Conditions MS Conditions Column ACQUITY BEH C µm; 2.1 x 100 LC ACQUITY UPLC Flow Rate 0.4 ml/min MPA Water with 0.1% FA MPB ACN with 0.1% FA Column Temp 30 C Inj. Vol 10 µl XEVO TQD ESI+ Capillary: 1.0 kv Source Temp: 150 C Desolvation Temp: 350 C Cone Gas Flow: 50 L/Hr Desolvation Gas Flow: 900 L/Hr MRM Transitions optimized individually Time Flow %A %B Curve Waters Corporation 25
26 Opioid Chromatography % Separation of isobaric compounds (highlighted compounds) 1, 3 2 4, , ,19 20 ACQUITY BEH C µm, 2.1 x 100mm Compound 1 Morphine-3β-D-glucuronide 2 Oxymorphone-3β-D-glucuronide 3 Hydromorphone-3β-D- glucuronide 4 Morphine-6β-D-glucuronide 5 Morphine 6 Oxymorphone 7 Hydromorphone 8 Codeine-6β-D-glucuronide 9 Dihydrocodeine 10 Codeine 11 Oxycodone 2013 Waters Corporation Time 12 6-Acetylmorphone (6-AM) 13 O-desmethyl Tramadol 14 Hydrocodone 15 Norbuprenorphine-glucuronide 16 Norfentanyl 17 Tramadol 18 Normeperedine 19 Meperidine 20 Buprenorphine-glucuronide 21 Norbuprenorphine 22 Fentanyl 23 Buprenorphine 24 EDDP+ 25 Propoxyphene 26 Methadone
27 % Recovery on Oasis MCX SPE 6 Lots of Urine 120% 100% 80% %R Recovery 60% 40% 20% 0% 2013 Waters Corporation 27
28 Improved Matrix Factors and %CV with Oasis MCX SPE vs. dilution - 6 Lots of Urine Mixed-mode SPE Dilution * * * Matrix Factors * * * * * * * * * 0.00 * Statistically significant difference in Matrix Factors (12/26 compounds) - reduced %CV in 23/26 compounds 2013 Waters Corporation 28
29 QC Results Diluted Urine QC Concentration(ng/mL) %CV Bias %CV Bias %CV Bias %CV Bias Morphine-3-gluc 10.3% -5.7% 6.1% -2.3% 2.3% -4.2% 6.2% -5.0% Oxymorphone-3-gluc 18.1% -8.7% 6.8% -2.8% 4.0% -8.1% 7.0% -8.5% Hydromorphone-3-gluc 14.5% 3.3% 4.5% 4.1% 6.9% -5.4% 5.8% -9.3% Morphine-6-gluc 23.1% 4.7% 17.5% -1.4% 9.3% -0.4% 3.5% -10.4% Morphine 26.9% -29.7% 7.9% 1.3% 9.4% 7.0% 16.6% 2.7% Oxymorphone 23.3% 19.7% 9.7% 9.9% 5.8% 0.7% 5.4% -10.0% Hydromorphone 14.1% 8.3% 5.0% 5.7% 5.1% 0.7% 3.4% -4.7% Codeine-6-β-d-gluc 11.5% -14.0% 7.0% -4.5% 8.0% -9.3% 4.4% -10.4% Dihydrocodeine 9.4% 10.0% 8.0% 14.8% 5.6% -2.1% 5.3% -3.2% Codeine 10.5% 5.3% 4.7% 2.0% 8.0% -5.5% 3.9% -8.5% Oxycodone 20.4% 0.3% 6.8% 5.6% 3.4% -2.8% 3.4% -4.9% 6-Acetylmorphone 7.7% -13.3% 9.5% -8.9% 2.8% -13.8% 5.2% -7.1% O-desmethyl Tramadol 3.6% -0.7% 4.9% 5.9% 3.3% -3.9% 2.5% -7.8% Hydrocodone 8.2% -10.0% 3.6% -4.2% 6.4% -9.1% 5.8% -14.7% Norbuprenorphine-gluc 5.3% -3.3% 2.7% 2.8% 5.0% -6.2% 3.0% -12.4% Norfentanyl 11.2% -18.7% 3.7% 6.9% 3.7% -3.6% 0.6% -7.9% Tramadol 1.5% -13.0% 3.6% -6.9% 1.3% -12.8% 0.8% -16.1% Normeperedine 4.6% -0.7% 5.1% 5.7% 3.1% -6.2% 0.7% -10.8% Meperidine 1.7% -2.3% 7.0% 3.2% 2.1% -5.5% 2.7% -8.2% Buprenorphine-gluc 4.5% -36.0% 3.6% -12.3% 4.9% -15.6% 2.1% -18.2% Norbuprenorphine 9.2% -4.7% 2.8% 6.2% 5.6% -3.0% 1.7% -9.0% Fentanyl 3.3% -6.7% 2.9% 3.9% 3.9% -4.1% 1.4% -8.2% Buprenorphine 6.4% -9.3% 3.8% 0.6% 3.7% -7.6% 2.3% -10.9% EDDP+ 1.7% -0.7% 3.3% 4.4% 1.0% -4.3% 2.1% -8.7% Propoxyphene 8.2% -6.7% 2.2% 1.2% 2.8% -8.1% 4.5% -12.5% Methadone 6.0% -7.0% 2.5% 0.7% 3.4% -6.9% 4.4% -12.6% Mean 7.5 ng/ml = 10.2% 11 compounds >10% 2013 Waters Corporation 29
30 QC Results Oasis MCX SPE QC Concentration(ng/mL) %CV Bias %CV Bias %CV Bias %CV Bias Morphine-3-gluc 8.3% -5.3% 5.2% -0.7% 2.2% 0.0% 3.6% -3.4% Oxymorphone-3-gluc 9.7% -1.0% 3.0% 2.5% 4.9% -4.0% 3.7% -7.0% Hydromorphone-3-gluc 7.8% 6.3% 5.8% 1.9% 2.9% 0.9% 3.7% -0.5% Morphine-6-gluc 8.7% 10.7% 6.7% -0.1% 5.1% -3.7% 4.0% -5.8% Morphine 10.1% 8.7% 7.7% 0.8% 5.1% -13.2% 4.3% -2.2% Oxymorphone 5.1% 4.7% 4.2% -2.3% 4.7% -2.6% 4.5% -3.6% Hydromorphone 1.6% 5.7% 3.0% 0.9% 3.7% -0.9% 1.2% -2.8% Codeine-6-β-d-gluc 4.0% 3.7% 3.8% -1.9% 5.0% 2.9% 2.6% 5.4% Dihydrocodeine 0.8% 2.0% 1.1% 1.1% 0.6% -2.5% 2.8% -5.5% Codeine 4.7% 2.3% 0.6% 1.1% 1.9% -1.9% 0.9% -3.7% Oxycodone 5.2% 1.0% 2.3% 0.7% 3.4% -2.2% 2.8% -5.5% 6-Acetylmorphone 5.3% 2.7% 4.3% 1.6% 2.3% -1.7% 0.7% -2.1% O-desmethyl Tramadol 1.9% 4.3% 1.3% 0.0% 0.7% -1.2% 0.7% -3.8% Hydrocodone 1.9% 1.3% 1.3% -0.7% 1.6% -2.3% 0.9% -4.7% Norbuprenorphine-gluc 3.6% 4.0% 3.1% 1.8% 3.9% 2.0% 1.3% 0.5% Norfentanyl 0.0% 1.3% 2.3% 3.3% 1.2% 0.4% 2.2% 1.7% Tramadol 0.0% 1.3% 0.3% 2.4% 0.8% -3.8% 0.5% -7.7% Normeperedine 2.0% -0.3% 1.6% 0.4% 1.2% -4.5% 1.4% -7.2% Meperidine 0.7% -1.0% 0.5% -2.5% 2.4% -3.1% 1.7% -3.0% Buprenorphine-gluc 2.7% 7.7% 1.8% 3.7% 1.6% 6.8% 1.3% 10.3% Norbuprenorphine 1.2% 3.0% 3.8% 3.6% 1.5% -1.6% 1.0% -5.7% Fentanyl 0.0% 1.3% 1.1% 2.4% 1.0% -2.7% 1.0% -3.2% Buprenorphine 2.3% 0.7% 1.9% 2.9% 1.9% -1.1% 1.3% -0.7% EDDP+ 1.3% 2.0% 1.1% 0.0% 0.9% -2.7% 1.1% -3.1% Propoxyphene 0.8% 0.7% 0.5% 4.5% 0.9% -2.6% 1.9% -5.3% Methadone 0.7% 1.0% 1.5% 4.3% 1.0% -1.4% 1.2% -3.4% Mean 7.5 ng/ml= 3.5% 1 point >10% Reduced Total Analytical Error vs. Dilute and Shoot 2013 Waters Corporation 30
31 Overview Goal of Sample Preparation Sample Preparation Options Application Examples Opioids and Metabolites in Oral Fluid Summary 2013 Waters Corporation 31
32 Opioids and Metabolites in Oral Fluid Oral fluid advantages Increasingly popular techniques Non-invasive Easily observed collection Reflective of recent use/impairment Can be correlated with plasma concentrations o Bases may be present at higher conc. than plasma Oral fluid considerations Limited sample volume Contamination from oral administration Collection challenges (devices/inconsistency) Protein content of oral fluid (0.3%) Salts, matrix components from stabilization buffers 2013 Waters Corporation 32
33 Extraction Methodology for Oral Fluid Oasis MCX µelution 96-Well Plate (Mixed-mode strong cation exchange SPE) Sample Pretreatment 1 ml oral fluid + 3 ml stabilizing buffer* Remove a 400 µl aliquot (100 µl oral fluid) Add 200 µl of 4% H 3 PO µl IS (500 ng/ml) Condition Plate 200 µl MeOH then 200 µl Water Load 100 µl pretreated sample Wash 200 µl of 2% formic acid; then 200 µl MeOH; then 200 µl IPA Elute 2 x 50 µl (60:40 ACN:IPA + 5% NH 4 OH) Selective cleanup for basic compounds µelution format Designed for small volumes Samples and elution volumes Evaporate under N 37 o C Reconstitute in 50 µl of starting mobile phase (2% ACN/0.1% FA) Inject 10 µl * Oral fluid collected using QuantiSal from Immunalysis Waters Corporation 33
34 %Recovery Using Oasis MCX µelution Plate 120% Recovery of Opioids from Oral Fluid 100% 80% 60% 40% 20% 0% Average Recovery = 91% 2013 Waters Corporation 34
35 Linearity and calibration curve results Compound R 2 Max. %CV Max. %Bias LOQ (ng/ml) Morphine % 9.7% 5 Oxymorphone % 1.9% 5 Hydromorphone % 1.6% 5 Dihydrocodeine % 5.9% 5 Codeine % 5.9% 5 Oxycodone % 6.8% 5 6-Acetylmorphone (6-AM) % 4.2% 5 O-desmethyl Tramadol % 1.7% 5 Hydrocodone % 2.3% 5 Norfentanyl % 3.2% 1.25 Tramadol % 3.6% 5 Normeperedine % 1.8% 5 Meperidine % 2.0% 5 Norbuprenorphine % 6.5% 5 Fentanyl % 1.5% 1.25 Buprenorphine % 2.0% 5 EDDP % 1.2% 5 Propoxyphene % 2.3% 5 Methadone % 2.2% ng/ml Calib. Curve ( for Fentanyl and norfentanyl All R 2 Values Waters Corporation 35
36 QC Results - Oral fluid QC Concentration (ng/ml) (N=4) Compound %CV Bias %CV Bias %CV Bias %CV Bias Morphine 15.3% 19.7% 2.7% 18.2% 12.2% 11.6% 6.9% 5.9% Oxymorphone 9.2% 2.7% 6.4% 3.3% 2.6% 4.1% 2.7% 5.1% Hydromorphone 7.7% 1.1% 3.6% 5.1% 3.2% 5.4% 3.8% 6.4% Dihydrocodeine 2.3% 6.7% 3.6% 11.4% 2.7% 4.4% 2.2% 1.5% Codeine 8.7% 7.2% 3.7% 11.7% 3.8% 4.3% 3.9% 1.4% Oxycodone 7.0% 5.3% 5.6% 10.6% 5.1% 7.5% 2.7% 2.2% 6-Acetylmorphone (6-AM) 5.3% 5.4% 3.6% 8.5% 3.6% 3.3% 7.1% 4.5% O-desmethyl Tramadol 5.6% 6.1% 2.5% 7.7% 2.1% 5.8% 1.7% 5.4% Hydrocodone 5.6% 6.4% 3.4% 4.6% 2.7% 4.7% 3.0% 6.6% Norfentanyl 7.0% 0.8% 3.9% 8.3% 2.9% 2.6% 3.3% 4.9% Tramadol 4.8% 6.4% 3.1% 8.8% 2.6% 6.7% 2.2% 4.8% Normeperedine 4.8% -0.7% 3.3% 3.5% 2.2% 3.1% 2.8% 2.4% Meperidine 5.5% 5.2% 4.1% 4.9% 2.6% 6.6% 2.5% 6.2% Norbuprenorphine 5.9% 5.4% 3.6% 8.3% 2.3% 4.8% 1.5% 2.9% Fentanyl 4.6% 4.8% 2.5% 7.4% 2.7% 6.8% 1.5% 6.4% Buprenorphine 4.5% 6.5% 2.8% 8.1% 3.0% 7.9% 1.5% 7.5% EDDP+ 4.7% 4.8% 2.4% 5.8% 2.7% 6.8% 2.5% 7.3% Propoxyphene 3.8% 6.8% 3.0% 8.6% 2.4% 7.0% 2.2% 7.0% Methadone 5.3% 6.1% 3.2% 8.0% 3.0% 6.8% 2.4% 6.5% ng/ml Calib. Curve Mean % Bias = 5.3% Mean %CV = 4.5% 2013 Waters Corporation 36
37 Sample Preparations Strategies for Opioids - Conclusions Urine and Oral Fluid Highly selective clean up Mixed mode SPE (MCX) Improved accuracy and precision vs. dilution µelution format ideal for limited sample volume (OF) Excellent linearity, analytical accuracy, and precision Waters Corporation 37
38 Overview Goal of Sample Preparation Sample Preparation Options Application Examples Synthetic Cannabinoids in Urine Summary 2013 Waters Corporation 38
39 Synthetic Cannabinoids Designer drugs that mimic the psychoactive effects of natural cannabinoids Often referred to or marketed as Spice compounds Labeled as not for human consumption and marketed as a legal alternative to natural cannabis Popularity has risen substantially in the last several years A growing challenge for law enforcement agencies and forensic laboratories Recent legislation has banned some of these compounds, but minor modifications are made to existing structures to circumvent existing laws Quantitative analysis in urine and whole blood 2013 Waters Corporation 39
40 Synthetic Cannabinoids in Urine Oasis HLB µelution Need to extract neutrals, bases, and acidic metabolites Clean up urine matrix Concentrate samples o No need for evaporation High recovery and sensitivity High throughput CORTECS Solid Core Columns 1.6 µm solid-core particles Highest efficiency column available 2013 Waters Corporation 40
41 Synthetic Cannabinoids and Metabolites No. Compound 1 AM RCS-4, M10 3 RCS-4, M11 4 AM JWH butanoic acid met. 6 JWH hydroxybutyl met. 7 JWH pentanoic acid met. 8 JWH-073 (+/-) 3-hydroxybutyl met. 9 JWH hydroxypentyl met. 10 JWH-018 (+/-) 4-hydroxypentyl met. 11 JWH RCS-4 14 JWH JWH XLR JWH JWH RCS-8 19 UR JWH AB AKB 48 Acids Bases Neutrals 2013 Waters Corporation 41
42 Extraction Methodology with the Oasis HLB µelution Plate Condition Plate 200 µl MeOH then 200 µl Water Sample Pretreatment Mix 1 ml urine ml of 0.8 potassium phosphate (ph 7.0) Add 10 µl of β-glucuronidase and incubate at 40 C for 1 hr Add 1.5 ml of 4% H 3 PO 4 Load 600 µl pretreated sample (200 µl urine) Wash 200 µl water, then 200 µl 50:50 H 2 O:MeOH Elute 2 x 50 µl 60:40 ACN:IPA Dilute with 75 µl of water Inject 5 µl 2013 Waters Corporation 42
43 UPLC and MS conditions UPLC Conditions MS Conditions Column CORTECS C µm; 2.1 x 100 XEVO TQD ESI+ LC ACQUITY UPLC I-Class Capillary: 1.0 kv Flow Rate 0.6 ml/min Source Temp: 150 C MPA Water with 0.1% FA Desolvation Temp: 600 C MPB ACN with 0.1% FA Cone Gas Flow: 0 L/Hr Column Temp 30 C Desolvation Gas Flow: 900 L/Hr Inj. Vol 5 µl MRM Transitions optimized individually Time Flow %A %B Curve Waters Corporation 43
44 Chromatogram for 22 Synthetic Cannabinoids and Metabolites 100 % % , 10 11, , Baseline separation of isobaric metabolites 22 Time 1) AM ) RCS4, M10 3) RCS-4, M11 4) AM ) JWH COOH met. 6) JWH OH met. 7) JWH COOH met. 8) JWH-073 (+/-) 3-OH met. 9) JWH OH met. 10) JWH-018 (+/-) 4-OH met. 11) JWH ) RCS-4 13) JWH ) JWH ) XLR-11 16) JWH ) JWH ) RCS-8 19) UR ) JWH ) AB ) AKB Time Column: CORTECS UPLC C 18, 2.1 x 100 mm; 1.6 µm 2013 Waters Corporation 44
45 Improved Resolution of CORTECS , 10 5) JWH COOH met. 6) JWH OH met. 7) JWH COOH met. 8) JWH-073 (+/-) 3-OH met. 9) JWH OH met. 10) JWH-018 (+/-) 4-OH met. % 5 7 ACQUITY UPLC BEH C x 100 mm Time , 10 % 5 7 CORTECS UPLC C x 100 mm 0 Time Waters Corporation 45
46 Recovery and Matrix Effects from Urine: Oasis HLB µelution Plates 120.0% 100.0% 80.0% Recovery Matrix Effects 60.0% 40.0% 20.0% 0.0% -20.0% -40.0% -60.0% -80.0% Average recovery was 74%. Matrix effects ranged from -49% (ion suppression) to 32% (enhancement), although most were less than 20%. Even in instances in which recovery was comparatively low, there was more than adequate sensitivity for the purposes of this assay Waters Corporation 46
47 Accuracy, Precision, and Sensitivity QC concentration (ng/ml) R 2 % Acc %CV %Acc %CV %Acc %CV Mean AM RCS4, M RCS4, M AM JWH COOH JWH OH Butyl JWH-018, 5-COOH JWH-073, 3-OH Butyl JWH-018, 5-OH Met JWH-018, 4-OH Met JWH RCS JWH JWH XLR JWH JWH RCS UR JWH AB AKB Calibration range ng/ml All accuracies within 15% of expected values. Most % CVs less than 10% and none greater than 15%. Limits of detection were as low as 0.1 ng/ml ; none greater than 2 ng/ml Waters Corporation 47
48 Overview Goal of Sample Preparation Sample Preparation Options Application Examples Synthetic Cannabinoids in Whole Blood Summary 2013 Waters Corporation 48
49 Whole Blood Extraction Methodology with Ostro Plate*
50 % Recovery and matrix effects of Synthetic Cannabinoids from Whole Blood Using Ostro Plates 130.0% 110.0% 90.0% 70.0% 50.0% 30.0% Recovery Matrix Effect 10.0% -10.0% -30.0% An average recovery of 92% for all compounds. Matrix effects were minimal Waters Corporation 50
51 Linearity and Analytical Sensitivity QC concentrations(ng/ml) Mean % Acc. R 2 %Acc. %CV %Acc. %CV %Acc. %CV AM % % % RCS4, M % % % RCS4, M % % % 98.9 AM % % % 98.2 JWH COOH % % % JWH OH Butyl % % % 96.3 JWH-018, 5-COOH % % % 97.4 JWH-073, 3-OH Butyl % % % 89.5 JWH-018, 5-OH Met % % % 94.3 JWH-018, 4-OH Met % % % 93.8 JWH % % % 96.8 RCS % % % 96.4 JWH % % % 94.5 JWH % % % 95.5 XLR % % % JWH % % % 91.0 JWH % % % 94.8 RCS % % % 98.5 UR % % % 93.8 JWH % % % 94.8 AB % % % 95.2 AKB % % % 96.4 Mean % Acc R 2 values of >0.99 for 21 of the 22 compounds Most % CVs less than 10% and none greater than 13%. Accurate at all QC levels 2013 Waters Corporation 51
52 Synthetic Cannabinoids - Conclusions Urine Single method for extracting neutral, acidic, and basic compounds o Possibility of using the same technique for related compounds Removes salts, enzymes, and buffers Rapid and simple sample preparation o 96-well plates utilized Achieved excellent recovery and sensitivity No evaporation and reconstitution steps necessary o µelution format Whole Blood Clean up highly complex matrix (Ostro) Removal of proteins, cellular debris, and phospholipids Rapid, universal method with minimal method development Excellent recovery with minimal matrix effects Excellent accuracy and precision 2013 Waters Corporation 52
53 Expanded Toxicology Panel Expanded Toxicology Panel Replace immunoassay screening o Single analysis vs. multiple methods o Improved specificity and sensitivity HPLC Column Comparison Attributes of CORTECS 2.7 µm and XBridge BEH Phenyl XP 2.5 µm columns Simplified Sample Preparation Strategy Simplified procedure using MCX µelution plates 2013 Waters Corporation 53
54 HPLC Column Comparisons Compound Key Expanded Tox Panel 1) Amphetamine 2) MDA 3) Methamphetamine 4) MDMA 5) Phentermine 6) MDEA 7) BZE 8) PCP 9) Nitrazepam 10) Oxazepam 11) Alprazolam 12) Lorazepam 13) Clonazepam 14) Flunitrazepam 15) Temazepam 16) Diazepam amines benzodiazepines 17) Morphine 18) Oxymorphone 19) Hydromorphone 20) Dihydrocodeine 21) Codeine 22) Oxycodone 23) 6-AM 24) O-desmethyl Tramadol 25) Hydrocodone 26) Norfentanyl 27) Tramadol 28) Normeperedine 29) Meperedine 30) Norbuprenorphine 31) Fentanyl 32) Buprenorphine 33) EDDP 34) Propoxyphene 35) Methadone opioids 2013 Waters Corporation 54
55 Method Parameters UPLC MS MPA MPB Col Temp I-Class, FL with Column Manager (CMA) Xevo TQD 0.1% Formic Acid 0.1% Formic Acid in ACN 30 C Inj. Vol 10 µl Columns CORTECS C 18, 2.7 µm; 3.0 x 50 mm XBridge BEH Phenyl XP, 2.5 µm; 3.0 x 50 mm Time (min) Flow (ml/min) % MPA % MPB Waters Corporation 55
56 Opioid Chromatography 100 % % CORTECS C µm 3.0 x 50 mm , Time XBridge BEH Phenyl XP 2.7 µm, 3.0 x 50 mm Time 17) Morphine 18) Oxymorphone 19) Hydromorphone 20) Dihydrocodeine 21) Codeine 22) Oxycodone 23) 6-AM 24) O-desmethyl Tramadol 25) Hydrocodone 26) Norfentanyl 27) Tramadol 28) Normeperedine 29) Meperedine 30) Norbuprenorphine 31) Fentanyl 32) Buprenorphine 33) EDDP 34) Propoxyphene 35) Methadone 2013 Waters Corporation 56
57 Enhanced Retention of Opiates 17) Morphine 100 CORTECS C µm 3.0 x 50 mm 25 19) Hydromorphone 21) Codeine 25) Hydrocodone % Time % XBridge BEH Phenyl XP 2.7 µm, 3.0 x 50 mm Time Waters Corporation 57
58 Amine Chromatography 100 % CORTECS C µm 3.0 x 50 mm 0 Time ) Amphetamine 2) MDA 3) Methamphetamine 4) MDMA 5) Phentermine 6) MDEA 7) BZE 8) PCP XBridge BEH Phenyl XP 2.7 µm, 3.0 x 50 mm % Time Waters Corporation 58
59 Benzodiazepine Chromatography 100 % CORTECS C µm 3.0 x 50 mm ) Nitrazepam 10) Oxazepam 11) Alprazolam 12) Lorazepam Time 13) Clonazepam 14) Flunitrazepam 15) Temazepam 16) Diazepam 100 XBridge BEH Phenyl XP 2.7 µm, 3.0 x 50 mm 15 % Time Waters Corporation 59
60 Performance Statistics and Conclusions Column Particle Size (µm) Pressure (Max) Mean Peak Width (sec) CORTECS C XBridge BEH Phenyl XP CORTECS High efficiency, narrow peak widths, and low pressure XBridge BEH Phenyl XP Enhanced retention of opiates and other polars 2013 Waters Corporation 60
61 Expanded Toxicology Panel Expanded Toxicology Panel Replace immunoassay screening o Single analysis vs. multiple methods o Improved specificity and sensitivity HPLC Column Comparison Attributes of CORTECS 2.7 µm and BEH Phenyl XP 2.5 µm columns Simplified Sample Preparation Strategy Universal simplified procedure using MCX µelution plates 2013 Waters Corporation 61
62 Simplified MCX procedure Compound Key Expanded Tox Panel 1 Amphetamine 2 MDA 3 MDMA 4 MDEA 5 BZE 6 PCP 7 7-Aminoclonazepam 8 alpha-oh Alprazolam 9 Oxazepam 10 Lorazepam 11 Clonazepam 12 Alprazolam 13 Temazepam 14 Diazepam 15 Morphine-3-gluc 16 Morphine-6-gluc 17 Morphine 18 Oxymorphone 19 Hydromorphone 20 Naloxone 21 Dihydrocodeine 22 Codeine 23 Noroxycodone 24 O-desmethyl Tramadol 25 6-MAM 26 Oxycodone 27 Hydrocodone 28 Norfentanyl 29 Tramadol 30 Tapentadol 31 Norbuprenorphine 32 Fentanyl 33 Buprenorphine 34 EDDP 35 Methadone 2013 Waters Corporation 62
63 Instrument Parameters UPLC MS MPA MPB Column Col Temp I-Class, FL with Column Manager (CMA) Xevo TQD 0.1% Formic Acid 0.1% Formic Acid in ACN BEH Phenyl; 1.7 µm, 2.1 x 100mm 40 C Inj. Vol 15 µl Time (min) Flow (ml/min) % MPA % MPB Waters Corporation 63
64 Chromatography 100 Amines, BZE, and PCP 100 Benzodiazepines % % Time Time Opioids and Others % Time Waters Corporation 64
65 Extraction Methodology for Urine Oasis MCX µelution Plate Protocol (Mixed-mode strong cation exchange SPE) In Well Hydrolysis 50 µl urine + 50 µl 0.1 M NH 4 OAc + 10 µl β-glucuronidase Add 200 µl 4% H 3 PO 4 Load Sample Wash 200 µl 0.02 N HCl in 20% MeOH Elute 2 x 50 µl (60:40 ACN:MeOH + 5% NH 4 OH) Pre-conditioning steps Eliminated Wash Steps Consolidated Evaporate Reconsititute with 50 ul 2% ACN/1% FA Inject 15 µl 2013 Waters Corporation 65
66 Recovery Simplified Protocol 120% 100% 80% 60% 40% 20% 0% Recovery Mean Recovery = 100% Compound LOD (ng/ml) Morphine-3-gluc 10 Morphine-6-gluc 10 Morphine 10 Oxymorphone 10 Hydromorphone 10 Amphetamine 1 Naloxone 10 Dihydrocodeine 10 Codeine 10 MDA 1 Noroxycodone 10 O-desmethyl Tramadol 1 6-MAM 10 Oxycodone 10 MDMA 1 Hydrocodone 10 MDEA 1 7-Aminoclonazepam 1 Norfentanyl 1 BZE 1 Tramadol 1 Tapentadol 1 Norbuprenorphine 10 PCP 1 Fentanyl 0.1 Buprenorphine 1 alpha-oh Alprazolam 10 EDDP 1 Oxazepam 1 Lorazepam 1 Clonazepam 1 Alprazolam 1 Methadone 1 Temazepam 1 Diazepam Waters Corporation 66
67 Overview Goal of Sample Preparation Sample Preparation Options Application Examples THC and Metabolites in Blood Summary 2013 Waters Corporation 67
68 THC and Metabolites in Whole Blood Assay Use Highly sensitive assay for THC and metabolites in whole blood Analytes THC, COOH-THC, OH-THC Goals Clean up whole blood matrix Maximize recovery and minimize matrix effects Need excellent linearity and sensitivity Selective extraction of acidic compounds (Oasis MAX) Short analytical run times Elimination of derivatization step prior to analysis Improved sample throughput vs. GC/MS 2013 Waters Corporation 68
69 Sample Preparation PPT Followed by Mixed Mode SPE Sample pretreatment (PPT and pretreatment) Oasis MAX Cartridge Protocol (Mixed-mode strong anion exchange SPE) Sample 0.2 ml whole blood Precipitate 0.4 ml ACN (added dropwise) Centrifuge 400 x g for 10 Transfer Supernatent Transfer supernatent (0.4 ml) To 0.6 ml 1% NH 4 OH Condition Cartridge 1 ml MeOH then 1 ml 1% NH 4 OH Load 1 ml prepared sample Wash 0.5 ml 50% ACN Elute 1.5 ml of 49:49:2 hexane:ethyl acetate:acetic acid Evaporate under N 2 at 40 C Reconstitute in ml 70% aqueous MeOH Inject 15 µl 2013 Waters Corporation 69
70 THC Chromatography 0.5 ng/ml in Whole Blood THC-COOH qualifier ion THC-COOH quantifier ion THC-OH qualifier ion LC System: ACQUITY UPLC Column: ACQUITY BEH C µm, 2.1 x 100 mm Flow: 400 µl/min MPA: 0.1% formic acid MPB: ACN Gradient: 60% B to 90% B over 4 minutes Mass spectrometer: XEVO TQ-S Ionization: ESI + Acquisition: MRM THC-OH quantifier ion Calibration Range: ng/ml THC qualifier ion THC quantifier ion 2013 Waters Corporation 70
71 Mean recovery and matrix effects 6 lots of whole blood Recovery and Matrix Effects Recovery Matrix Effects THC-OH THC-COOH THC Mean % recovery and matrix effects for cannabinoids spiked in whole blood at low (0.5 ng/ml), medium (5.0 ng/ml), and high (25 ng/ml) concentrations. The error bars are standard deviations Waters Corporation 71
72 Inter-Day Accuracy and Precision 3.33 ng/ml Inter-day Accuracy % Target ng/ml ng/ml 3.33 ng/ml Inter-day Precision %RSD ng/ml ng/ml THC-OH THC-COOH THC Inter-day accuracy and precision assessed by analyzing three quality control (QC) concentrations over 5 different days. The mean achieved values for the QC replicates over the 5-day period at the three concentration levels were within 10% of target, and the %RSD was <10% Waters Corporation 72
73 Conclusions The challenges posed by the matrix (whole blood) and analytical requirements were best met with a two step process PPT followed by MAX Excellent sensitivity, linearity, accuracy and precision Minimal matrix effects Rapid analytical run time 2013 Waters Corporation 73
74 Overview Goal of Sample Preparation Sample Preparation Options Application Examples Summary 2013 Waters Corporation 74
75 Summary of Applications and Sample Preparation Strategies Application Matrix Solution Benefits Opiates Urine EN Oral Fluid EN Urine Oral Fluid Oasis MCX µelution ACQUITY BEH C 18 Oasis MCX µelution ACQUITY BEH C 18 Good recovery for all compounds Improved linearity, accuracy and precision vs Dilution Reduced matrix effects Good recovery for all compounds Linear, accurate and precise data Limited sample volume Synthetic Cannabinoids Urine EN Whole Blood EN Expanded Tox Panel THC and Metabolites EN Urine Oasis HLB µelution Sorbent appropriate for multiple chemotypes Linear, accurate and precise CORTECS C 18 Effective cleanup Concentration without evaporation Whole Blood Urine Whole Blood Ostro CORTECS C 18 Oasis MCX µelution ACQUITY BEH Phenyl PPT and Oasis MAX ACQUITY BEH C 18 Protein and phospholipid removal Linear, accurate and precise Minimal matrix effects Fast and Easy Minimal method development Excellent recovery for all compound classes Simplified SPE Method Rapid Sample Prep and analysis Sensitive, linear, accurate and precise Good recovery and minimal matrix effects 2013 Waters Corporation 75
76 Acknowledgements Sherri Naughton Nebila Idris Erin Chambers Michelle Wood Robert Lee 2013 Waters Corporation 76
77 Thank You for Attending! Post-Event Landing Page % Promotional Offer On CORTECS Columns and Oasis uelution Plates 30% Offer on Ostro Plates 20% offer on BEH Columns (ACQUITY and Xbridge) Full Webinar Recording of Today s Session w/pdf Slide Deck Compilation of TODAY S KEY Literature, Brochures etc For Questions and to Submit your Ideas for our Next Topic Please - mychemrep@waters.com Visit Us at SOFT: Booth # 101/200, October 21st 23rd 2013 Waters Corporation 77
78 Thank You 2013 Waters Corporation 78
Direct Analysis of Urinary Opioids and Metabolites by Mixed-Mode µelution SPE Combined with UPLC/MS/MS for Forensic Toxicology
Direct Analysis of Urinary Opioids and Metabolites by Mixed-Mode µelution SPE Combined with UPLC/MS/MS for Forensic Toxicology Jonathan P. Danaceau, Erin E. Chambers, and Kenneth J. Fountain Waters Corporation,
More information[ APPLICATION NOTE ] APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS KEYWORDS
A Comprehensive Method for the Analysis of Pain Management Drugs and Drugs of Abuse Incorporating Simplified, Rapid Mixed-Mode SPE with UPLC-MS/MS for Clinical Research Jonathan P. Danaceau, Scott Freeto,
More informationA Comprehensive Screening of Illicit and Pain Management Drugs from Whole Blood Using SPE and LC/MS/MS
A Comprehensive Screening of Illicit and Pain Management Drugs from Whole Blood Using SPE and LC/MS/MS Introduction Drug analysis from whole blood is gaining popularity due to a more complete measurement
More informationA Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography
Application Note LCMS-109 A Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography Time of Flight (LC-TOF) Mass Spectrometry Introduction Many clinical
More informationComparison of Different Whole Blood Sample Pretreatment Methods for Targeted Analysis of Basic Drugs
Seyed Sadjadi, Shahana Huq, Sean Orlowicz and Laura Snow Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA Comparison of Different Whole Blood Sample Pretreatment Methods for Targeted Analysis
More informationPerformance of an ultra low elution volume 96-well plate
Performance of an ultra low elution volume 96-well plate Claude R. Mallet, Ziling Lu, Jeff R. Mazzeo, Uwe D. Neue Waters Corporation PittCon 2003 March 10-14 2003 Orlando, Florida Today s Challenges Faced
More informationLCMS-8050 Drugs of Abuse: 113 Analytes with Polarity Switching
Liquid Chromatography Mass Spectrometry SSI-LCMS-8 LCMS-8 Drugs of Abuse: Analytes with Polarity Switching LCMS-8 Summary Seventy six analytes and their internal standards are described below. Multiple
More informationFast and easy separation of 23 drugs of abuse. including high, stable resolution of isobaric opioids from human urine by UHPLC-MS/MS
TECHNICAL NOTE 21883 Fast and easy separation of 23 drugs of abuse including high, stable resolution of isobaric opioids from human urine by UHPLC-MS/MS Authors Kean Woodmansey 1, Jon Bardsley 1 and Stacy
More informationValidation of an Automated Method to Remove
Shahana Wahab Huq 1, Richard Thomas 2, Agnes Cua 2, Seyed Sadjadi 1 1 Phenomenex, 411 Madrid Avenue, Torrance, CA 951 2 Precision Toxicology, 33 Bunker Hill Street, San Diego, CA 9219 Validation of an
More informationLC-MS/MS Method for the Determination of 21 Opiates and Opiate Derivatives in Urine
LC-MS/MS Method for the Determination of 21 Opiates and Opiate Derivatives in Urine J. Jones, S. Westwood, T. Liddicoat, L. Pereira, T. Edge Thermo Fisher Scientific, Manor Park, Runcorn, UK Overview Purpose:
More informationDr. Erin E. Chambers Waters Corporation. Presented by Dr. Diego Rodriguez Cabaleiro Waters Europe Waters Corporation 1
Development of an SPE-LC/MS/MS Assay for the Simultaneous Quantification of Amyloid Beta Peptides in Cerebrospinal Fluid in Support of Alzheimer s Research Dr. Erin E. Chambers Waters Corporation Presented
More informationPaul D. Rainville Ph.D. Health Sciences Group Waters Corporation Waters Corporation 1
A new level of sensitivity and standardization: The promise of integrated micro fluidic devices coupled with mass spectrometry for the analysis of biofluids Paul D. Rainville Ph.D. Health Sciences Group
More informationDevelopment of a Bioanalytical Method for Quantification of Amyloid Beta Peptides in Cerebrospinal Fluid
Development of a Bioanalytical Method for Quantification of Amyloid Beta Peptides in Cerebrospinal Fluid Joanne ( 乔安妮 ) Mather Senior Scientist Waters Corporation Data courtesy of Erin Chambers and Mary
More informationExtraction of Synthetic and Naturally Occurring Cannabinoids in Urine Using SPE and LC-MS/MS
Extraction of Synthetic and Naturally Occurring Cannabinoids in Urine Using SPE and LC-MS/MS UCT Part Numbers SSHLD063 Styre Screen HLD 60 mg, 6 ml column SPHPHO6001-5 Select ph Buffer Pouches 100 mm Phosphate
More informationRapid and Sensitive Analysis of a 93-Compound Forensic Panel in Urine using the QTRAP /Triple Quad 4500 LC- MS/MS System
Rapid and Sensitive Analysis of a 93-Compound Forensic Panel in Urine using the QTRAP /Triple Quad 4500 LC- MS/MS System Xiang He, 1 Casey Burrows 1, Matthew Noestheden 2, Michael Jarvis, 2 Adrian Taylor,
More information4.5 Minute Analysis of Benzodiazepines in Urine and Whole Blood Using LC/MS/MS and an Ultra Biphenyl Column
Clinical, Forensic & Toxicology Applications 4.5 Minute Analysis of Benzodiazepines in Urine and Whole Blood Using LC/MS/MS and an Ultra Biphenyl Column By Amanda Rigdon Abstract A rapid, sensitive method
More informationHigh-Throughput Quantitative LC-MS/MS Analysis of 6 Opiates and 14 Benzodiazepines in Urine
High-Throughput Quantitative LC-MS/MS Analysis of and 14 Benzodiazepines in Urine Bill Yu, Kristine Van Natta, Marta Kozak, Thermo Fisher Scientific, San Jose, CA Application Note 588 Key Words Opiates,
More informationE XCEL LENCE JUST GOT BETTER UCT FORENSICS CLEAN SCREEN XCEL SPE COLUMNS
FORENSICS UCT E XCEL LENCE JUST GOT BETTER CLEAN SCREEN XCEL SPE COLUMNS CLEAN SCREEN XCEL COLUMNS EXTRACTION OF BASIC DRUGS AND METABOLITES FROM URINE/ BLOOD USING SPE CARTRIDGES 130mg Clean Screen Xcel
More informationAgilent Clinical LC/MS: Review of Established LC-MS QQQ Clinical Research Applications. dr. Jan Srbek, HPST. Page 1
Agilent Clinical LC/MS: Review of Established LC-MS QQQ Clinical Research Applications dr. Jan Srbek, HPST Page 1 Major LC-MS Clinical Applications Steroids/Endocrinology Vitamin D Testosterone, Estradiol
More informationA Novel Solution for Vitamin K₁ and K₂ Analysis in Human Plasma by LC-MS/MS
A Novel Solution for Vitamin K₁ and K₂ Analysis in Human Plasma by LC-MS/MS By Shun-Hsin Liang and Frances Carroll Abstract Vitamin K₁ and K₂ analysis is typically complex and time-consuming because these
More informationQuantitative Determination of Drugs of Abuse in Human Plasma and Serum by LC/MS/MS Using Agilent Captiva EMR Lipid Cleanup
Application Note Forensic Testing Quantitative Determination of Drugs of Abuse in Human Plasma and Serum by LC/MS/MS Using Agilent Captiva EMR Lipid Cleanup Author Limian Zhao Agilent Technologies, Inc.
More informationOvercoming the Challenges of Sample Preparation and LC/MS/MS Method Development for Clinical Applications
Overcoming the Challenges of Sample Preparation and LC/MS/MS Method Development for Clinical Applications Speaker: Sky Countryman, Manager of PhenoLogix and Applied Technologies, Phenomenex Webinar Host:
More informationRemoval of Triton X-100 from Plasma Samples Using Mixed-Mode Solid Phase Extraction (SPE)
Removal of Triton X- from Plasma Samples Using Mixed-Mode Solid Phase Extraction (SPE) Jonathan P. Danaceau, Erin Chambers, and Kenneth J. Fountain Waters Corporation, 34 Maple Street, Milford, MA USA
More informationHigh Throughput Extraction of Opiates from Urine and Analysis by GC/MS or LC/MS/MS)
High Throughput Extraction of Opiates from Urine and Analysis by GC/MS or LC/MS/MS) Michael Rummel, Matthew Trass, Michael Campognone, and Sky Countryman Phenomenex, Inc., 411 Madrid Avenue, Torrance,
More informationAnalysis of Testosterone, Androstenedione, and Dehydroepiandrosterone Sulfate in Serum for Clinical Research
Analysis of Testosterone, Androstenedione, and Dehydroepiandrosterone Sulfate in Serum for Clinical Research Dominic Foley, Michelle Wills, and Lisa Calton Waters Corporation, Wilmslow, UK APPLICATION
More informationUsing Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population
Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population Adam S. Ptolemy 1, Colleen Murray 2, Edward Dunn 3,
More informationAnalysis of Rosuvastatin in Dried Blood Spot and Plasma Using ACQUITY UPLC with 2D Technology
Analysis of Rosuvastatin in Dried Blood Spot and Plasma Using ACQUITY UPLC with 2D Technology Claude Mallet, 1 Jennifer Simeone, 2 Paul Rainville 3 1 Workflow Integration Group, Separations Technologies,
More informationSample Preparation Techniques for Biological Matrices: Finding the right balance to achieve optimal results
Sample Preparation Techniques for Biological Matrices: Finding the right balance to achieve optimal results Presenter: Diana Wang Applications Engineer SPP-Support@agilent.com 1 Today s Agenda - Why sample
More informationOpiates, Opioids and Benzodiazepines, Amphetamines & Illicit Drug Forensic Analysis by LC/MS
Opiates, Opioids and Benzodiazepines, Amphetamines & Illicit Drug Forensic Analysis by LC/MS Julie Cichelli, PhD Agilent Technologies Application Engineer April 29, 2014 Agenda A method for the rapid analysis
More informationThe Development of LC/MS Methods for Determination of MDMA (Ecstasy) and Metabolites in Biological Samples
WA20714 The Development of LC/MS Methods for Determination of MDMA (Ecstasy) and Metabolites in Biological Samples Michael S. Young and Kevin M. Jenkins Waters Corporation, 34 Maple Street, Milford, MA
More informationQuantitative Determination of Drugs of Abuse in Human Whole Blood by LC/MS/MS Using Agilent Captiva EMR Lipid Cleanup
Application Note Forensic Testing Quantitative Determination of Drugs of Abuse in Human Whole Blood by LC/MS/MS Using Agilent Captiva EMR Lipid Cleanup Author Limian Zhao Agilent Technologies, Inc. Abstract
More information[ APPLICATION NOTE ] Oasis PRiME HLB Cartridge for Cleanup of Infant Formula Extracts Prior to UPLC-MS/MS Multiresidue Veterinary Drugs Analysis
Prior to UPLC-MS/MS Multiresidue Veterinary Drugs Analysis Michael S Young and Kim Van Tran Waters Corporation, Milford, MA, USA APPLICATION BENEFITS Efficient, timesaving multiclass/ multiresidue methodology
More informationFully Automated Online Sample Preparation and LC-MS/MS Analysis of Drugs of Abuse in Oral Fluids
PO-CON1753E Fully Automated Online Sample Preparation and LC-MS/MS Analysis of Drugs of Abuse in Oral Fluids ASMS 2017 TP-442 Joshua F. Emory 1, Nathan DeFreitas 2, Michael Roberts 1, Manoj Tyagi 2, M.
More informationSimultaneous Analysis of Intact Human Insulin and Five Analogs in Human Plasma Using μelution SPE and a CORTECS UPLC Column
Simultaneous Analysis of Intact Human Insulin and Five Analogs in Human Plasma Using μelution SPE and a CORTECS UPLC Column Erin E. Chambers and Kenneth J. Fountain Waters Corporation, Milford, MA, USA
More informationFast quantitative Forensic Analysis of THC and its Metabolites in Biological Samples using Captiva EMR- Lipid and LC/MSMS
Fast quantitative Forensic Analysis of THC and its Metabolites in Biological Samples using Captiva EMR- Lipid and LC/MSMS Christophe Deckers, M.Sc. Sample prep Application Scientist Types of ``Interferences``
More informationA Novel Platform of On-line Sample Pre-treatment and LC/MS/MS Analysis for Screening and Quantitation of Illicit Drugs in Urine
PO-CON737E A Novel Platform of On-line Sample Pre-treatment and LC/MS/MS Analysis for Screening and Quantitation of Illicit Drugs in Urine ASMS 7 WP 353 Shao Hua Chia ; Zhi Wei Edwin Ting ; Daisuke Kawakami
More informationProviding a Universal, One-step Alternative to Liquid-Liquid Extraction in Bioanalysis
Providing a Universal, ne-step Alternative to Liquid-Liquid Extraction in Bioanalysis Jessalynn P. Wheaton, Erin E. Chambers, and Kenneth J. Fountain APPLICATIN BENEFITS n Simple, one-step sample preparation
More information1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia
NEW TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. Test Code Test Name Effective Date
More informationLC Application Note. Dangerous driver?
LC Application Note Dangerous driver? www.palsystem.com Dangerous driver? Robert M. Sears 1 ; Kenneth C. Lewis 2 ; and Kim Gamble 3 1 SC Law Enforcement Division, Columbia, SC 29221; 2 OpAns LLC, Durham
More informationProof of Concept for Automated SPE/HPLC/MS/MS Methods to Replace Traditional Immunoassay with MS Confirmation of Driving Under the Influence Samples
Proof of Concept for Automated SPE/HPLC/MS/MS Methods to Replace Traditional Immunoassay with MS Confirmation of Driving Under the Influence Samples Robert M. Sears, Toxicology Technical Leader 1, Kenneth
More informationRapid Analysis of Bisphenols A, B, and E in Baby Food and Infant Formula Using ACQUITY UPLC with the Xevo TQD
Rapid Analysis of Bisphenols A, B, and E in Baby Food and Infant Formula Using ACQUITY UPLC with the Xevo TQD Claude R. Mallet Waters Corporation, Milford, MA, USA A P P L I C AT ION B E N E F I T S This
More informationValidation Report for the Neogen Fentanyl Kit for ELISA Screening of Whole Blood and Urine Specimens
Validation Report for the Neogen Fentanyl Kit for ELISA Screening of Whole Blood and Urine Specimens This document describes the validation of a Neogen Fentanyl kit for the semi-quantitative analysis of
More informationMatrix Factor Determination with the Waters Regulated Bioanalysis System Solution
Matrix Factor Determination with the Waters Regulated Bioanalysis System Solution Joanne Mather, Steve Cubbedge, Debadeep Bhattacharya, and Robert S. Plumb Waters Corporation, Milford, MA, U.S. A P P L
More informationBETA-GLUCURONIDASE PRODUCT LINE INNOVATION THROUGH CHEMISTRY. FORENSICS
FORENSICS BETA-GLUCURONIDASE PROD LINE INNOVATION THROUGH CHEMISTRY ABALONASE Purified Beta-Glucuronidase Formula Clean, Rapid And Reliable Shown from left to right: Abalonase purified Beta-glucuronidase
More informationThe Development of LC/MS Methods for Determination of Polar Drugs of Abuse in Biological Samples
WA20259 The Development of LC/MS Methods for Determination of Polar Drugs of Abuse in Biological Samples Michael S. Young and Kevin M. Jenkins Waters Corporation, 34 Maple Street, Milford, MA 01757 Introduction
More informationChallenges in Developing an Ultra-Sensitive Bioanalytical Method for Ethinylestradiol in Human Plasma
Challenges in Developing an Ultra-Sensitive Bioanalytical Method for Ethinylestradiol in uman Plasma Jessalynn P. Wheaton, Erin E. Chambers, and Kenneth J. Fountain Waters Corporation, 34 Maple Street,
More informationModernizing the Forensic Lab with LC-MS/MS Technology
Modernizing the Lab with LC-MS/MS Technology Innovative SCIEX Analytical Tools for the Rapid Identification of Drugs of Abuse in Samples Oscar G. Cabrices 1, Holly McCall 1, Xiang He 1, Alexandre Wang
More informationO O H. Robert S. Plumb and Paul D. Rainville Waters Corporation, Milford, MA, U.S. INTRODUCTION EXPERIMENTAL. LC /MS conditions
Simplifying Qual/Quan Analysis in Discovery DMPK using UPLC and Xevo TQ MS Robert S. Plumb and Paul D. Rainville Waters Corporation, Milford, MA, U.S. INTRODUCTION The determination of the drug metabolism
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years
Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - MEDICATION DETECTED (PARENT DRUG
More informationRapid and Accurate LC-MS/MS Analysis of Nicotine and Related Compounds in Urine Using Raptor Biphenyl LC Columns and MS-Friendly Mobile Phases
Clinical, Forensic & Toxicology Applications Rapid and Accurate LC-MS/MS Analysis of Nicotine and Related Compounds in Urine Using Raptor Biphenyl LC Columns and MS-Friendly Mobile Phases By Shun-Hsin
More informationDienes Derivatization MaxSpec Kit
Dienes Derivatization MaxSpec Kit Item No. 601510 www.caymanchem.com Customer Service 800.364.9897 Technical Support 888.526.5351 1180 E. Ellsworth Rd Ann Arbor, MI USA TABLE OF CONTENTS GENERAL INFORMATION
More informationEvaluation of the Impact of Expanding ELISA Screening in DUID Investigations. Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K.
Evaluation of the Impact of Expanding ELISA Screening in DUID Investigations Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K. Logan FSF Emerging Forensic Scientist Award Oral Presentation Disclosure
More informationA RAPID AND SENSITIVE ANALYSIS METHOD OF SUDAN RED I, II, III & IV IN TOMATO SAUCE USING ULTRA PERFORMANCE LC MS/MS
A RAPID AD SESITIVE AALYSIS METD OF SUDA RED I, II, III & IV I TOMATO SAUCE USIG ULTRA PERFORMACE LC MS/MS Choon Keow G, aomi TAAKA, Michelle KIM, Swee Lee YAP Waters Asia, Regional Technology Center,
More informationPAIN PANEL. Research and Solutions
PAIN PANEL Research and Solutions Pain management drug use and abuse has increased significantly in recent years. The 21 National Survey on Drug Use & Health (NSDUH) reports that 17.3% of first-time drug
More informationA High Sensitivity UPLC/MS/MS Method for the Analysis of Clopidogrel and Clopidogrel Carboxylic Acid Metabolite in Human K 2 EDTA Plasma
A High Sensitivity UPLC/MS/MS Method for the Analysis of Clopidogrel and Clopidogrel Carboxylic Acid Metabolite in Human K 2 EDTA Plasma Jennifer L. Simeone, Paul D. Rainville, Robert S. Plumb Waters Corporation,
More informationAdvancing your Forensic Toxicology Analyses; Adopting the Latest in Mass Spectrometry Innovations
Advancing your Forensic Toxicology Analyses; Adopting the Latest in Mass Spectrometry Innovations For Research Use Only. Not for use in diagnostic procedures. 1 2015 AB Sciex RUO-MKT-11-1018-A For research
More informationReduced Ion Suppression and Improved LC/MS Sensitivity with Agilent Bond Elut Plexa
Reduced Ion Suppression and Improved LC/MS Sensitivity with Agilent Bond Elut Plexa Application Note Small Molecule Pharmaceuticals & Generics Author Mike Chang Agilent Technologies, Inc. 5 Commercentre
More informationUPLC-MS/MS Analysis of Azole Antifungals in Serum for Clinical Research
Stephen Balloch and Gareth Hammond Waters Corporation, Wilmslow, UK APPLICATION BENEFITS Analytical selectivity afforded by mass selective detection Wide linear measuring range Simple, inexpensive sample
More informationScreening by immunoassay and confirmation & quantitation by GC-MS of buprenorphine and norbuprenorphine in urine, whole blood and serum
Screening by immunoassay and confirmation & quantitation by GC-MS of buprenorphine and norbuprenorphine in urine, whole blood and serum NINA KANGAS, SIRPA MYKKÄNEN, SANNA KYLLÖNEN, PÄIVI RAJALA, KARI ARINIEMI
More informationA FORENSIC TOXICOLOGY METHOD FOR THE DETERMINATION OF DESOMORPHINE, HEROIN, METHADONE, BUPRENORPHINE AND METABOLITES IN URINE USING LC/MS QQQ
FORENSICS MARKET A FORENSIC TOXICOLOGY METHOD FOR THE DETERMINATION OF DESOMORPHINE, HEROIN, METHADONE, BUPRENORPHINE AND METABOLITES IN URINE USING LC/MS QQQ Desomorphine, also known by its street name
More informationValidation of a Benzodiazepine and Z-Drug Method Using an Agilent 6430 LC/MS/MS
Validation of a Benzodiazepine and Z-Drug Method Using an Agilent 6430 LC/MS/MS Application Note Forensics Authors Jason Hudson, Ph.D., James Hutchings, Ph.D., and Rebecca Wagner, Ph.D. Virginia Department
More informationUltra-Fast Forensic Toxicological Screening and Quantitation under 3 Minutes using SCIEX X500R QTOF System and SCIEX OS 1.
Ultra-Fast Forensic Toxicological Screening and Quantitation under 3 Minutes using SCIEX X500R QTOF System and SCIEX OS 1.0 Software Xiang He 1, Adrian M. Taylor 2, Michael Jarvis 2 and Alexandre Wang
More informationUCT STYRE SCREEN INNOVATION THROUGH CHEMISTRY
UCT STYRE SCREEN PO L Y M E R I C S O R B E N T S P E INNOVATION THROUGH CHEMISTRY STYRE SCREEN STYRE SCREEN Extraction Columns Styre Screen extraction sorbents are formulated with an ultra clean, highly
More informationA Definitive Lipidomics Workflow for Human Plasma Utilizing Off-line Enrichment and Class Specific Separation of Phospholipids
A Definitive Lipidomics Workflow for Human Plasma Utilizing Off-line Enrichment and Class Specific Separation of Phospholipids Jeremy Netto, 1 Stephen Wong, 1 Federico Torta, 2 Pradeep Narayanaswamy, 2
More informationThe Drug Testing Process. Employer or Practice
Disclosures Clinical Professor, Jefferson Medical College BOD MROCC [Medical Review Officer Certification Council] BOD National Sleep Foundation BOD POEMS [Pennsylvania Occupational & Environmental Medicine
More informationComprehensive Study of SLE as a Sample. Preparation Tool for Bioanalysis
Comprehensive Study of SLE as a Sample Preparation Tool for Bioanalysis Wan Wang, Warren Chen, Jerry Wang Bonna-Agela Technologies 179 Southern Street, West TEDA, Tianjin, China Abstract A simple, fast,
More informationReducing Sample Volume and Increasing Sensitivity for the Quantification of Human Insulin and 5 Analogs in Human Plasma Using ionkey/ms
Reducing Sample Volume and Increasing Sensitivity for the Quantification of Human Insulin and 5 Analogs in Human Plasma Using ionkey/ms Erin E. Chambers and Kenneth J. Fountain Waters Corporation, Milford,
More informationSimplifying Solid-Phase Extraction [ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]
Simplifying Solid-Phase Extraction [ OASIS SOLID-PHASE EXTRACTION PRODUCTS ] Through the combination of innovative sorbent technology and hardware design, Oasis Products have become the first choice in
More informationApplication Note LCMS-108 Quantitation of benzodiazepines and Z-drugs in serum with the EVOQ TM LC triple quadrupole mass spectrometer
Application Note LCMS-108 Quantitation of benzodiazepines and Z-drugs in serum with the EVOQ TM LC triple quadrupole mass spectrometer Abstract This study demonstrates a sensitive, rapid and reliable research
More informationSimultaneous Determination of Prescription and Designer Benzodiazepines in Urine and Blood by SPE and LC-MS/MS
Simultaneous Determination of Prescription and Designer Benzodiazepines in Urine and Blood by SPE and LC-MS/MS UCT Part Numbers CSXCE106 Clean Screen XCEL I 130mg / 6mL SPE Cartridge SPHACE5001-5 Select
More informationRapid Analysis of Water-Soluble Vitamins in Infant Formula by Standard-Addition
Rapid Analysis of Water-Soluble Vitamins in Infant Formula by Standard-Addition Evelyn Goh Waters Pacific, Singapore APPLICATION BENEFITS This method allows for the simultaneous analysis of 12 water-soluble
More informationDevelopment of a High Sensitivity SPE-LC-MS/MS Assay for the Quantification of Glucagon in Human Plasma Using the ionkey/ms System
Development of a High Sensitivity SPE-LC-MS/MS Assay for the Quantification of Glucagon in Human Plasma Using the ionkey/ms System Mary E. Lame, Erin E. Chambers, Sukhdev S. Bangar, and Kenneth J. Fountain
More informationPAIN PANEL. Application Guide. Screen 41 compounds in under 4 minutes
Application Guide PAIN PANEL Screen 41 compounds in under 4 minutes Solutions for large compound screens and individual compound classes such as benzodiazepines, opiates, and more Achieve resolution of
More informationDETERMINATION OF CANNABINOIDS, THC AND THC-COOH, IN ORAL FLUID USING AN AGILENT 6490 TRIPLE QUADRUPOLE LC/MS
FORENSICS AND TOXICOLOGY ANALYSIS DETERMINATION OF CANNABINOIDS, THC AND THC-COOH, IN ORAL FLUID USING AN AGILENT 6490 TRIPLE QUADRUPOLE LC/MS Solutions for Your Analytical Business Markets and Applications
More informationRapid LC/TOF MS for Analytical Screening of Drugs in the Clinical Research Lab
Application Note Clinical Research Rapid LC/TOF MS for Analytical Screening of Drugs in the Clinical Research Lab Authors Adam Barker 1,2, Frederick G. Strathmann 3, Natalie N. Rasmussen 4, and Carrie
More informationAmphetamines, Phentermine, and Designer Stimulant Quantitation Using an Agilent 6430 LC/MS/MS
Amphetamines, Phentermine, and Designer Stimulant Quantitation Using an Agilent 643 LC/MS/MS Application Note Forensics Authors Jason Hudson, Ph.D., James Hutchings, Ph.D., and Rebecca Wagner, Ph.D. Virginia
More informationOverview. Introduction. Experimental. Cliquid Software for Routine LC/MS/MS Analysis
A Fast and Sensitive LC/MS/MS Method for the Quantification and Confirmation of 3 Benzodiazepines and Nonbenzodiazepine Hypnotics in Forensic Urine Samples Cliquid Software for Routine LC/MS/MS Analysis
More informationQuantitative Analysis of Opiates in Urine Using RRHT LC/MS/MS. Application. Authors. Introduction. Abstract. Forensics
Quantitative Analysis of piates in Urine Using RRHT LC/MS/MS Application Forensics Authors Sheher Mohsin Agilent Technologies, Inc. 10 N. Martingale Rd., Suite 550 Schaumburg, IL 60173 USA Yanan Yang Agilent
More informationQuantitative Analysis of Drugs of Abuse in Urine using UHPLC Coupled to Accurate Mass AxION 2 TOF Mass Spectrometer
application Note Liquid Chromatography/ Mass Spectrometry Authors Sharanya Reddy Blas Cerda PerkinElmer, Inc. Shelton, CT USA Quantitative Analysis of Drugs of Abuse in Urine using UHPLC Coupled to Accurate
More informationLC-MS/MS Method for the Determination of Tenofovir from Plasma
LC-MS/MS Method for the Determination of Tenofovir from Plasma Kimberly Phipps, Thermo Fisher Scientific, Runcorn, Cheshire, UK Application Note 687 Key Words SPE, SOLA CX, Hypersil GOLD, tenofovir Abstract
More informationDrugs of Abuse in Oral Fluids: Automated SPE Extraction and LC/MS/MS Determination using a Robotic Autosampler
Drugs of Abuse in Oral Fluids: Automated SPE Extraction and LC/MS/MS Determination using a Robotic Autosampler Fred D. Foster 1, John R. Stuff 1, Jacqueline A. Whitecavage 1, Edward A. Pfannkoch 1, Mark
More informationBETA-GLUCURONIDASE PRODUCT LINE INNOVATION THROUGH CHEMISTRY FORENSICS
FORENSICS BETA-GLUCURONIDASE PROD LINE INNOVATION THROUGH CHEMISTRY ABALONASE Purified Beta-Glucuronidase Formula Clean, Rapid And Reliable Shown from left to right: Abalonase purified Beta-glucuronidase
More informationQuantification of Budesonide Using UPLC and Xevo TQ-S
Tirupateswara Rao B., Sudarshan Mantha, and Gopal Vaidyanathan Waters India MS Application Laboratory, Bangalore, India A P P L I C AT ION B E N E F I T S This work demonstrates the benefits of the Regulated
More informationUPLC/MS Monitoring of Water-Soluble Vitamin Bs in Cell Culture Media in Minutes
UPLC/MS Monitoring of Water-Soluble Vitamin Bs in Cell Culture Media in Minutes Catalin E. Doneanu, Weibin Chen, and Jeffrey R. Mazzeo Waters Corporation, Milford, MA, U.S. A P P L I C AT ION B E N E F
More informationRemoval of Lipids for the Analysis of Toxicological Compounds in Plasma by LC/MS/MS
Removal of Lipids for the Analysis of Toxicological Compounds in Plasma by LC/MS/MS Enhanced Matrix Removal Lipid Dispersive Cleanup Application Note Small Molecule, Toxicology Author Joan Stevens, Agilent
More informationRapid Hydrolysis of Benzodiazepines in Urine. Alicia Zook 1 and Crystal Xander B.S. 2. Cedar Crest College, Allentown, PA 1
Rapid Hydrolysis of Benzodiazepines in Urine Alicia Zook 1 and Crystal Xander B.S. 2 Cedar Crest College, Allentown, PA 1 Health Network Laboratories, Allentown, PA 2 Abstract: Benzodiazepines are sedative/hypnotic
More informationAlcohol Biomarkers by UHPLC-MS/MS
Alcohol Biomarkers by UHPLC-MS/MS Application #AN9 ACE Excel. C8 x. mm EXL--U A: mm ammonium fluoride B: MeCN....... ml/ µl C AB SCIEX triple quad Negative ESI MRM Source temperature: C IonSpray voltage:
More informationDetermination of 78 Banned or Controlled Racing Industry Drugs in Horse Urine Using SPE and LC-MS/MS
Determination of 78 Banned or Controlled Racing Industry Drugs in Horse Urine Using SPE and LC-MS/MS UCT Part Numbers XRDAH203 Gravity Flow XtrackT DAU 200 mg, 3 ml column SPHPHO6001-5 Select ph Buffer
More information[ APPLICATION NOTE ] UPLC-MS/MS Analysis of 45 Amino Acids Using the Kairos Amino Acid Kit for Biomedical Research INTRODUCTION APPLICATION BENEFITS
UPLC-MS/MS Analysis of 45 Amino Acids Using the Kairos Amino Acid Kit for Biomedical Research Padhraic Rossiter, 1 Jaime Salcedo Dominguez, 1 Jennifer Warren, 1 Norma Breen, 1 Lisa Calton 2 1 Waters Corporation,
More informationMETHAMPHETAMINE & AMPHETAMINE
METHAMPHETAMINE & AMPHETAMINE Enantiomers from Urine Rapid and Accurate Chiral Separation Polysaccharide Chiral Chiral LC LC Columns and SFC PHEN-RUO-49 Revision: Lux 3 µm AMP Column High Efficiency LC/MS/MS
More informationAutomated Targeted screening of Benzodiazepines in urine using LDTD-MS/MS at 400 samples per hour rate
Automated Targeted screening of Benzodiazepines in urine using LDTD-MS/MS at 400 samples per hour rate Pierre Picard, Alex Birsan, Serge Auger, Annie-Claude Bolduc and Jean Lacoursière Phytronix Technologies
More informationWorkflow for Screening and Quantification of the SAMHSA (NIDA) Panel in Urine Using UHPLC-TOF
APPLICATIO OTE Liquid Chromatography/ Mass Spectrometry Authors: Avinash Dalmia Joanne Mather PerkinElmer, Inc. Shelton, CT Workflow for Screening and Quantification of the SAMHSA (IDA) Panel in Urine
More informationAlcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082
Alcohol The alcohol of interest is ethanol. Ethanol has a sedative effect in the brain. Ethanol intoxication symptoms include blurred vision, slurred speech, poor coordination and difficulty thinking depending
More informationApplication Note. Abstract. Authors. Pharmaceutical
Analysis of xycodone and Its Metabolites-oroxycodone, xymorphone, and oroxymorphone in Plasma by LC/MS with an Agilent ZRBAX StableBond SB-C18 LC Column Application ote Pharmaceutical Authors Linda L.
More informationORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS
ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS Barry K Logan PhD, DABFT National Director of Forensic Services, NMS Labs Willow Grove PA Disclaimer
More informationLC/MS/MS Analysis of Metabolites of Synthetic Cannabinoids JWH-018 and JWH-073 in Urine
Abstract A liquid chromatographic method was developed to resolve a comprehensive set of metabolites of JWH-018 and JWH-073. In addition to the chromatographic analysis method, an extraction method was
More informationDrug Adherence Assessment Report
Prescribed Medications: Drug Adherence Assessment Report FENTANYL, OXYCODONE CONSISTENT RESULTS - REPORTED MEDICATION DETECTED (PARENT DRUG AND/OR METABOLITE) REPORTED ANTICIPATED TEST PRESCRIPTION (S)
More informationUltrafast Analysis of Benzodiazepines in Urine by the Agilent RapidFire High-Throughput Triple Quadrupole Mass Spectrometry System
Ultrafast Analysis of Benzodiazepines in Urine by the Agilent RapidFire High-Throughput Triple Quadrupole Mass Spectrometry System Application Note Forensic Toxicology Authors Nikunj R. Parikh, Michelle
More information